

Trust Headquarters
Russells Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-062025-0001680

Date: 2.7.25

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

I have a freedom of information request regarding the treatment of renal cell carcinoma. Could you please answer the following questions:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib - 0
- Axinitib - 3
- Cabozantinib - 1
- Everolimus - 0
- Lenvatinib + Everolimus - 0
- Lenvatinib + Pembrolizumab - 4
- Nivolumab monotherapy - 1
- Nivolumab + Cabozantinib - 2
- Nivolumab + Ipilimumab - 1
- Pazopanib - 1
- Pembrolizumab monotherapy - 3
- Pembrolizumab + Axitinib - 0
- Radiotherapy only - 0
- Sunitinib - 7
- Temsirolimus - 0
- Tivozanib - 1
- Other active systemic anti-cancer therapy - 0
- Palliative care only - 0

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta) - 0
- Cabozantinib (Cometriq) - 1
- Nivolumab (Opdivo) - 1

- Nivolumab + Cabozantinib (Opdivo + Cometriq) - **2**
- Nivolumab + Ipilimumab (Opdivo + Yervoy) - **1**
- Lenvatinib + Pembrolizumab + (Kispalyx + Keytruda) - **4**

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy) - **1**
- Nivolumab + Ipilimumab - **0**
- Nivolumab + Cabozantinib - **0**
- Avelumab + Axitinib - **0**
- Lenvatinib + Pembrolizumab + (Kispalyx + Keytruda) - **0**

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?
- 25 patients

Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so, please provide the name of each trial and number of patients that are taking part?

- No trials at present

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team

The Dudley Group NHS Foundation Trust